PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
4.31%
Gross profit growth 1.25-1.5x GNPX's 2.95%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth less than half of GNPX's 16.08%. David Dodd would verify if efficiency advantage is sustainable.
-40.17%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-8.25%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
8.31%
EBITDA growth exceeding 1.5x GNPX's 3.13%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth exceeding 1.5x GNPX's 3.10%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
12.55%
Pre-tax income growth exceeding 1.5x GNPX's 2.91%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth above 1.5x GNPX's 67.79%. Michael Burry would check for concerning trends.
12.55%
Net income growth exceeding 1.5x GNPX's 2.91%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth 1.25-1.5x GNPX's 12.70%. Bruce Berkowitz would examine sustainability.
15.52%
Diluted EPS growth 1.25-1.5x GNPX's 12.70%. Bruce Berkowitz would examine sustainability.
3.21%
Share count reduction exceeding 1.5x GNPX's 11.24%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x GNPX's 11.21%. David Dodd would verify capital allocation.